What is Envoy Medical's pre-tax stock-based compensation cost?

Envoy Medical (COCH) reported pre-tax stock-based compensation cost of $44K in Q1 2026.

How has Envoy Medical's pre-tax stock-based compensation cost changed year-over-year?

Envoy Medical's pre-tax stock-based compensation cost decreased by 72.5% year-over-year, from $160K to $44K.

Revenue$39.0K-15.2%

Gross profit-$274.0K-52.2%

Operating income-$6.0M-16.7%

Net income-$4.4M+12.9%

EPS (diluted)-$0.08+72.4%

Cash & equivalents$25.3M+376%

Total debt$919.0K-2.8%

Total equity$10.2M+142%

Total assets$29.8M+187%

Operating cash flow-$6.1M-62.7%

CapEx$172.0K—

Free cash flow-$5.9M-28.5%

Market cap$61M+83.5%

P/S260.7×+111×

Gross margin-310.7%+31.6pp

Operating margin-9,881.2%+805pp

Net margin-9,875.6%+771pp

FCF margin-7,626.6%-652pp

Return on equity328.7%—

Debt / equity0.1×—

Current ratio2.3×+1.2×

Reported directly by Envoy Medical in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Envoy Medical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Envoy Medical's pre-tax stock-based compensation cost?: Envoy Medical (COCH) reported pre-tax stock-based compensation cost of $44K in Q1 2026.
How has Envoy Medical's pre-tax stock-based compensation cost changed year-over-year?: Envoy Medical's pre-tax stock-based compensation cost decreased by 72.5% year-over-year, from $160K to $44K.